Advances in Cancer Research (eBook, ePUB)
105,95 €
105,95 €
inkl. MwSt.
Sofort per Download lieferbar
53 °P sammeln
105,95 €
Als Download kaufen
105,95 €
inkl. MwSt.
Sofort per Download lieferbar
53 °P sammeln
Jetzt verschenken
Alle Infos zum eBook verschenken
105,95 €
inkl. MwSt.
Sofort per Download lieferbar
Alle Infos zum eBook verschenken
53 °P sammeln
Advances in Cancer Research (eBook, ePUB)
- Format: ePub
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei
bücher.de, um das eBook-Abo tolino select nutzen zu können.
Hier können Sie sich einloggen
Hier können Sie sich einloggen
Sie sind bereits eingeloggt. Klicken Sie auf 2. tolino select Abo, um fortzufahren.
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei bücher.de, um das eBook-Abo tolino select nutzen zu können.
Advances in Cancer Research, Volume 148 , the latest release in this ongoing, well-regarded serial, provides invaluable information on the exciting and fast-moving field of cancer research.
Provides the latest information on cancer research | Offers outstanding and original reviews on a range of cancer research topics | Serves as an indispensable reference for researchers and students alike
- Geräte: eReader
- mit Kopierschutz
- eBook Hilfe
- Größe: 14.18MB
Andere Kunden interessierten sich auch für
- Advances in Cancer Research (eBook, ePUB)105,95 €
- Advances in Cancer Research (eBook, ePUB)105,95 €
- Louis J. CataniaThe Paradox of the Immune System (eBook, ePUB)114,95 €
- Hepatobiliary Cancers: Translational Advances and Molecular Medicine (eBook, ePUB)105,95 €
- Novel Approaches to Colorectal Cancer (eBook, ePUB)105,95 €
- Mechanisms and Therapy of Liver Cancer (eBook, ePUB)105,95 €
- Autophagy and Senescence in Cancer Therapy (eBook, ePUB)105,95 €
-
-
-
Advances in Cancer Research, Volume 148, the latest release in this ongoing, well-regarded serial, provides invaluable information on the exciting and fast-moving field of cancer research.
- Provides the latest information on cancer research
- Offers outstanding and original reviews on a range of cancer research topics
- Serves as an indispensable reference for researchers and students alike
Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.
Produktdetails
- Produktdetails
- Verlag: Elsevier Science & Techn.
- Seitenzahl: 330
- Erscheinungstermin: 26. Juli 2020
- Englisch
- ISBN-13: 9780128203286
- Artikelnr.: 61681434
- Verlag: Elsevier Science & Techn.
- Seitenzahl: 330
- Erscheinungstermin: 26. Juli 2020
- Englisch
- ISBN-13: 9780128203286
- Artikelnr.: 61681434
Paul B. Fisher, MPh, PhD, FNAI, Professor and Chairman, Department of Human and Molecular Genetics, Director, VCU Institute of Molecular Medicine Thelma Newmeyer Corman Chair in Cancer Research in the VCU Massey Cancer Center, VCU, School of Medicine, Richmond, VA, and Emeritus Professor, Columbia University, College of Physicians & Surgeons, New York, NY. Dr. Fisher is among the top 10% of NIH funded investigators over the past 35-years, published approximately 625 papers and reviews, and has 55 issued patents. He pioneered novel gene/discovery approaches (subtraction hybridization), developed innovative therapeutic approaches (Cancer Terminator Viruses), presented numerous named and distinguished lectures, founded several start-up companies, was Virginia Outstanding Scientist of 2014 and elected to the National Academy of Inventors in 2018. Dr. Fisher is a prominent nationally and internationally recognized cancer research scientist focusing on understanding the molecular and biochemical basis of cancer development and progression to metastasis and using this garnered information to develop innovative approaches for diagnosing and treating cancer. He discovered and patented novel genes and gene promoters relevant to cancer growth control, differentiation and apoptosis. His discoveries include the first cloning of p21 (CDK inhibitor), human polynucleotide phosphorylase, mda-9/syntenin (a pro-metastatic gene), mda-5 and mda-7/IL-24, which has shown promising clinical activity in Phase I/II clinical trials in patients with advanced cancers. Dr. Fisher alsohas a documented track record as a successful seasoned entrepreneur. He was Founder and Director of GenQuest Incorporated, a functional genomics company, which merged with Corixa Corporation in 1998, traded on NASDAQ and was acquired by GlaxoSmithKline in 2006. He discovered the cancer-specific PEG-Prom, which is the core technology of Cancer Targeting Systems (CTS, Inc.), a Virginia/Maryland-based compan
y (at Johns Hopkins Medical Center) focusing on imaging and therapy ("theranostics?) of metastatic cancer (2014) by Drs. Fisher and Martin G. Pomper. He co-founded InVaMet Therapeutics (IVMT) and InterLeukin Combinatorial Therapies (ILCT) with Dr. Webster K. Cavenee (UCSD) (2017/2018).
y (at Johns Hopkins Medical Center) focusing on imaging and therapy ("theranostics?) of metastatic cancer (2014) by Drs. Fisher and Martin G. Pomper. He co-founded InVaMet Therapeutics (IVMT) and InterLeukin Combinatorial Therapies (ILCT) with Dr. Webster K. Cavenee (UCSD) (2017/2018).
1. Epigenetic regulation of cancer stem cell and tumorigenesisKezhou Zhu, Victoria Xie and Suyun Huang2. Vascular mimicry: Triggers, molecular interactions and in vivo modelsStephen L. Wechman, Luni Emdad, Devanand Sarkar, Swadesh K. Das and Paul B. Fisher3. Biology, pathology, and therapeutic targeting of RASJ. Matthew Rhett, Imran Khan and John P. O'Bryan4. Cyclin D-CDK4/6 functions in cancerXueliang Gao, Gustavo W. Leone and Haizhen Wang5. SPARC-p53: The double agents of cancerDenise Camacho, Joana P. Jesus, António M. Palma, Sofia A. Martins, Alexandre Afonso, Maria Leonor Peixoto, Christopher J Pelham and Rajan Gogna6. Giants and monsters: Unexpected characters in the story of cancer recurrence Shai White-Gilbertson and Christina Voelkel-Johnson7. Ca2+ as a therapeutic target in cancer Scott Gross, Pranava Mallu, Hinal Joshi, Bryant Schultz, Christina Go and Jonathan Soboloff
1. Epigenetic regulation of cancer stem cell and tumorigenesisKezhou Zhu, Victoria Xie and Suyun Huang2. Vascular mimicry: Triggers, molecular interactions and in vivo modelsStephen L. Wechman, Luni Emdad, Devanand Sarkar, Swadesh K. Das and Paul B. Fisher3. Biology, pathology, and therapeutic targeting of RASJ. Matthew Rhett, Imran Khan and John P. O'Bryan4. Cyclin D-CDK4/6 functions in cancerXueliang Gao, Gustavo W. Leone and Haizhen Wang5. SPARC-p53: The double agents of cancerDenise Camacho, Joana P. Jesus, António M. Palma, Sofia A. Martins, Alexandre Afonso, Maria Leonor Peixoto, Christopher J Pelham and Rajan Gogna6. Giants and monsters: Unexpected characters in the story of cancer recurrence Shai White-Gilbertson and Christina Voelkel-Johnson7. Ca2+ as a therapeutic target in cancer Scott Gross, Pranava Mallu, Hinal Joshi, Bryant Schultz, Christina Go and Jonathan Soboloff